Lupin shares fall over 4%. Should you buy, sell or hold? Here’s what brokerages say

Lupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferies, Kotak, and Bernstein maintained a reduce, underperform, and market-perform rating, respectively, on the stock. Jefferies found the gSpiriva approval positive but widely anticipated and indicated an expensive PE valuation. While Kotak believes gSpiriva’s upside is priced in, it stays cautious given Lupin’s weak execution record and subpar margin practice. Additionally, Bernstein stated that Lupin is trading higher than Sun Pharma.